Tag: Amgen

New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations

THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1  as well as a sub-analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER). Additional abstracts […]

Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events

THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization. Low-density lipoprotein cholesterol […]

Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that as part of the Company’s commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha® (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex® (on-body infusor […]

Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen

PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study […]

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. With the […]

FDA Approves Amgen’s Repatha® (evolocumab) To Prevent Heart Attack And Stroke

THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug Administration (FDA) approved Repatha® (evolocumab) as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.1 “We are pleased […]